Seth Lederman - Feb 15, 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Stock symbol
TNXP
Transactions as of
Feb 15, 2022
Transactions value $
$0
Form type
4
Date filed
2/17/2022, 04:17 PM
Previous filing
Sep 28, 2021
Next filing
Mar 28, 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +5M $0.00 5M Feb 15, 2022 Common Stock 5M $0.21 Direct F1, F3
transaction TNXP Stock Option Award $0 +5M $0.00 5M Feb 15, 2022 Common Stock 5M $0.41 Direct F2, F3
transaction TNXP Stock Option Award $0 +5M $0.00 5M Feb 15, 2022 Common Stock 5M $0.62 Direct F2, F3
transaction TNXP Stock Option Award $0 +5M $0.00 5M Feb 15, 2022 Common Stock 5M $0.83 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance.
F3 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.